Real-world data show diroximel fumarate well-tolerated, beneficial for MS patients

Patients with MS who took diroximel fumarate reported physical benefits, including slowed disease progression and decreased relapses, according to data presented at the Consortium of Multiple Sclerosis Centers annual meeting.
“Diroximel fumarate (DRF) is a next-generation oral fumarate approved in the United States and Europe for patients with relapsing forms of multiple sclerosis,” Meghan Garabedian, CRNP, a nurse practitioner at the University of Pennsylvania Neuroscience Center, and colleagues wrote in a poster. “DRF has the same pharmacologically active metabolite as

Patients with MS who took diroximel fumarate reported physical benefits, including slowed disease progression and decreased relapses, according to data presented at the Consortium of Multiple Sclerosis Centers annual meeting.
“Diroximel fumarate (DRF) is a next-generation oral fumarate approved in the United States and Europe for patients with relapsing forms of multiple sclerosis,” Meghan Garabedian, CRNP, a nurse practitioner at the University of Pennsylvania Neuroscience Center, and colleagues wrote in a poster. “DRF has the same pharmacologically active metabolite as